Novartis Financial Statements
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
143.75+0.64 (+0.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 143.75 -0.01%
Novartis revenue and earnings
Net income was $13.98 billion (+17.1% year over year). Diluted earnings per share came in at $7.15, up from $5.87.
Summary generated from market data by MetaCap's automated system. Methodology
Novartis income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 13.70B | 12.83B | 12.47B | 11.58B | 11.73B | 15.12B | 14.43B | 14.51B | 13.63B | 17.52B |
| Gross Profit | 42.98B | 38.90B | 34.19B | 31.88B | 32.24B | 34.78B | 34.25B | 31.59B | 29.77B | 31.92B |
| Operating Expenses | 25.33B | 24.35B | 24.42B | 23.93B | 22.18B | 24.63B | 25.17B | 23.19B | 21.07B | 23.65B |
| Research & Development | 11.20B | 10.02B | 11.37B | 9.17B | 8.64B | 8.98B | 9.40B | 8.49B | 8.39B | 9.04B |
| Selling, General & Admin | 13.25B | 12.57B | 12.52B | 12.19B | 12.83B | 14.20B | 14.37B | 13.72B | 12.46B | 14.19B |
| Operating Income | 17.64B | 14.54B | 9.77B | 7.95B | 10.06B | 10.15B | 9.09B | 8.40B | 8.70B | 8.27B |
| Interest Expense | 1.14B | 1.01B | 855.00M | 800.00M | 787.00M | 869.00M | 850.00M | 932.00M | 750.00M | 707.00M |
| Pretax Income | 16.35B | 13.64B | 9.12B | 7.18B | 24.53B | 9.88B | 8.94B | 14.10B | 9.10B | 7.82B |
| Income Tax | 2.38B | 1.70B | 551.00M | 1.13B | 1.63B | 1.81B | 1.79B | 1.29B | 1.60B | 1.12B |
| Net Income | 13.98B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.73B | 12.61B | 7.70B | 6.71B |
| Net Income growth (YoY) | +17.11% | -19.59% | +113.52% | -71.05% | +197.58% | -31.20% | -6.97% | +63.72% | +14.76% | — |
| EPS (Basic) | 7.21 | 5.92 | 7.15 | 3.19 | 10.71 | 3.55 | 5.12 | 5.44 | 3.28 | 2.82 |
| EPS (Diluted) | 7.15 | 5.87 | 7.10 | 3.17 | 10.63 | 3.52 | 5.06 | 5.38 | 3.25 | 2.80 |
| Shares Outstanding (Basic) | 1.94B | 2.02B | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B |
| Shares Outstanding (Diluted) | 1.96B | 2.04B | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B |
This table shows 10 annual periods of Novartis's income statement, from FY 2025 back to FY 2016, across 14 line items including cost of revenue, gross profit, operating expenses. Values in USD; B = billions, M = millions. Fiscal periods follow NVS's reporting calendar. What is a income statement?